Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension

Novartis296 enrolled

Overview

This study will evaluate efficacy and safety data for benazepril/hydrochlorothiazide in adult Chinese patients with mild to moderate essential hypertension. Patients whose blood pressure is not adequately controlled with benazepril monotherapy during a 4 week run-in period will be randomly allocated to double blind treatment over 8 weeks with either a combination of benazepril/hydrochlorothiazide per day or continuation of benazepril per day.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

296

Conditions

Hypertension

Interventions

Benazepril plus hydrochlorothiazideDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female patients, age 18 or older * Given informed consent * Diagnosed as having mild to moderate essential hypertension Exclusion Criteria: * Severe hypertension * Significant preexisting cardiovascular and cerebrovascular disease * Diabetes mellitus type 1 or poorly controlled diabetes mellitus type II * Advanced renal impairment Other protocol-defined inclusion/exclusion criteria may apply.

Locations (1)

Novartis

Beijing, China

Outcomes

Primary Outcomes

Change in diastolic blood pressure from baseline to week 8

Secondary Outcomes

Change in systolic blood pressure from baseline to week 8

Proportion of patients with blood pressure less than 140/90 mmHg at week 8

Ambulant blood pressure monitoring profiles at baseline and week 8

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.